Nonalcoholic fatty liver disease and type 2 diabetes: an observational and Mendelian randomization study

Introduction Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are both chronic multisystem diseases that cause tremendous health burdens worldwide. Previous epidemiological studies have found a bidirectional relationship between these two diseases; however, their causality remains largely unknown. We aim to examine the causal relationship between NAFLD and T2DM. Methods The observational analysis included 2,099 participants from the SPECT-China study and 502,414 participants from the UK Biobank. Logistic regression and Cox regression models were used to examine the bidirectional association between NAFLD and T2DM. Two-sample Mendelian randomization (MR) analyses were conducted to investigate the causal effects of the two diseases using summary statistics of genome-wide association studies from the UK Biobank for T2DM and the FinnGen study for NAFLD. Results During the follow-up, 129 T2DM cases and 263 NAFLD cases were observed in the SPECT-China study, and 30,274 T2DM cases and 4,896 NAFLD cases occurred in the UK Biobank cohort. Baseline NAFLD was associated with an increased risk of incident T2DM in both studies (SPECT-China: OR: 1.74 (95% confidence interval (CI): 1.12–2.70); UK Biobank: HR: 2.16 (95% CI: 1.82–2.56)), while baseline T2DM was associated with incident NAFLD in the UK Biobank study only (HR: 1.58). Bidirectional MR analysis showed that genetically determined NAFLD was significantly associated with an increased risk of T2DM (OR: 1.003 (95% CI: 1.002–1.004, p< 0.001)); however, there was no evidence of an association between genetically determined T2DM and NAFLD (OR: 28.1 (95% CI: 0.7–1,143.0)). Conclusions Our study suggested the causal effect of NAFLD on T2DM development. The lack of a causal association between T2DM and NAFLD warrants further verification.

[1]  K. Chayama,et al.  Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020 , 2021, Journal of Gastroenterology.

[2]  H. Tilg,et al.  Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals , 2020, Gut.

[3]  C. Willer,et al.  Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping. , 2020, Journal of hepatology.

[4]  Z. Pang,et al.  Famine Exposure in Early Life and Risk of Metabolic Syndrome in Adulthood: Comparisons of Different Metabolic Syndrome Definitions , 2019, Journal of diabetes research.

[5]  H. Tilg,et al.  Gut Dysfunction and Non-alcoholic Fatty Liver Disease , 2019, Front. Endocrinol..

[6]  M. Stepanova,et al.  Epidemiology of chronic liver diseases in the USA in the past three decades , 2019, Gut.

[7]  Tom R. Gaunt,et al.  Liver Function and Risk of Type 2 Diabetes: Bidirectional Mendelian Randomization Study , 2019, Diabetes.

[8]  B. Cha,et al.  Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis , 2018, Diabetes & metabolism journal.

[9]  E. Bonora,et al.  Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis , 2018, Diabetes Care.

[10]  A. Lonardo,et al.  Nonalcoholic fatty liver disease: Evolving paradigms , 2017, World journal of gastroenterology.

[11]  H. Te,et al.  Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States , 2017, PloS one.

[12]  A. McCullough,et al.  Natural History of Nonalcoholic Fatty Liver Disease , 2016, Digestive Diseases and Sciences.

[13]  M. Jensen,et al.  Is Exposure to Famine in Childhood and Economic Development in Adulthood Associated With Diabetes? , 2015, The Journal of clinical endocrinology and metabolism.

[14]  M. Carstensen,et al.  Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. , 2015, Cell metabolism.

[15]  C. Byrne,et al.  NAFLD: a multisystem disease. , 2015, Journal of hepatology.

[16]  P. Elliott,et al.  UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age , 2015, PLoS medicine.

[17]  Jimmy D Bell,et al.  External validation of the fatty liver index and lipid accumulation product indices, using 1H-magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals. , 2014, European journal of endocrinology.

[18]  Matthias Blüher,et al.  Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance. , 2014, Cell metabolism.

[19]  A. Canbay,et al.  Extrahepatic complications of nonalcoholic fatty liver disease , 2014, Hepatology.

[20]  S. Wild,et al.  Resolution of fatty liver and risk of incident diabetes. , 2013, The Journal of clinical endocrinology and metabolism.

[21]  P. Edwards,et al.  Pleiotropic roles of bile acids in metabolism. , 2013, Cell metabolism.

[22]  S. Friedman,et al.  Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid‐induced liver injury in superobese patients with nonalcoholic steatohepatitis , 2013, Hepatology.

[23]  S. Wild,et al.  Combined Influence of Insulin Resistance, Overweight/Obesity, and Fatty Liver as Risk Factors for Type 2 Diabetes , 2012, Diabetes Care.

[24]  P. O S I T I O N S T A T E M E N T Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.

[25]  S. Summers,et al.  Ceramides as modulators of cellular and whole-body metabolism. , 2011, The Journal of clinical investigation.

[26]  V. Basevi Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.

[27]  T. Joh,et al.  Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup , 2010, Journal of gastroenterology and hepatology.

[28]  J Wouter Jukema,et al.  Unraveling the directional link between adiposity and inflammation: a bidirectional Mendelian randomization approach. , 2009, The Journal of clinical endocrinology and metabolism.

[29]  George Davey Smith,et al.  Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology , 2008, Statistics in medicine.

[30]  F. Schmidt Meta-Analysis , 2008 .

[31]  S. Ebrahim,et al.  'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? , 2003, International journal of epidemiology.

[32]  Erick M Remer,et al.  The utility of radiological imaging in nonalcoholic fatty liver disease. , 2002, Gastroenterology.

[33]  G. McCaughan,et al.  Epidemiology and Etiologic Associations of Non-alcoholic Fatty Liver Disease and Associated HCC. , 2018, Advances in experimental medicine and biology.

[34]  L. Henry,et al.  NAFLD AND NASH: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018 .

[35]  S. Summers,et al.  CerS2 Haploinsufficiency Inhibits β-Oxidation and Confers Susceptibility to Diet-Induced Steatohepatitis and Insulin Resistance. , 2014, Cell metabolism.

[36]  P. Macfarlane,et al.  Unraveling the Directional Link between Adiposity and Inflammation: A Bidirectional Mendelian Randomization Approach. , 2009, Endocrine reviews.

[37]  Diagnosis and Classification of Diabetes Mellitus , 2003 .